[{"orgOrder":0,"company":"United Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Dinutuximab","moa":"Disialoganglioside GD2","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"United Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"United Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Eusa Pharma","sponsor":"BeiGene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Dinutuximab","moa":"Disialoganglioside GD2","graph1":"Oncology","graph2":"Approved","graph3":"Eusa Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"solution for infusion","sponsorNew":"Eusa Pharma \/ BeiGene","highestDevelopmentStatusID":"12","companyTruncated":"Eusa Pharma \/ BeiGene"},{"orgOrder":0,"company":"Eusa Pharma","sponsor":"Recordati","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Acquisition","leadProduct":"Dinutuximab","moa":"Disialoganglioside GD2","graph1":"Oncology","graph2":"Approved","graph3":"Eusa Pharma","amount2":0.84999999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.84999999999999998,"dosageForm":"Infusion","sponsorNew":"Eusa Pharma \/ Recordati","highestDevelopmentStatusID":"12","companyTruncated":"Eusa Pharma \/ Recordati"},{"orgOrder":0,"company":"St. Jude Children\u2019s Research Hospital","sponsor":"Renaissance Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Dinutuximab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"St. Jude Children\u2019s Research Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"St. Jude Children\u2019s Research Hospital \/ Renaissance Pharma","highestDevelopmentStatusID":"8","companyTruncated":"St. Jude Children\u2019s Research Hospital \/ Renaissance Pharma"},{"orgOrder":0,"company":"Essential Pharma","sponsor":"AGC Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Agreement","leadProduct":"Dinutuximab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Essential Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Essential Pharma \/ AGC Biologics","highestDevelopmentStatusID":"8","companyTruncated":"Essential Pharma \/ AGC Biologics"},{"orgOrder":0,"company":"Apeiron Biologics","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Acquisition","leadProduct":"Dinutuximab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Apeiron Biologics","amount2":0.13,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Apeiron Biologics \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"14","companyTruncated":"Apeiron Biologics \/ Ligand Pharmaceuticals"}]

Find Clinical Drug Pipeline Developments & Deals for Dinutuximab

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Ligand acquires Apeiron Biologics pipeline which also includes Qarziba (dinutuximab beta), it is indicated for the treatment of high-risk neuroblastoma in patients aged 12 months and above.

                          Brand Name : Qarziba

                          Molecule Type : Large molecule

                          Upfront Cash : $100.0 million

                          July 08, 2024

                          Lead Product(s) : Dinutuximab

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : Ligand Pharmaceuticals

                          Deal Size : $128.0 million

                          Deal Type : Acquisition

                          blank

                          02

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : AGC Biologics will produce Hu1418K322A (Hu14.18), a humanised monoclonal antibody being developed for Essential Pharma for the treatment of high-risk neuroblastoma (HRNB).

                          Brand Name : Hu14.18K322A

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          June 11, 2024

                          Lead Product(s) : Dinutuximab,Cyclophosphamide,Topotecan Hydrochloride

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : AGC Biologics

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          03

                          St. Jude Children’s Research Hospital

                          Country arrow
                          Pharmtech & Ingredients
                          Not Confirmed

                          St. Jude Children’s Research Hospital

                          Country arrow
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Under the agreement, Renaissance gains exclusive development, manufacturing and commercialisation rights for Hu14.18K322A, an anti GD2 humanised mAb in development by St. Jude for the treatment of newly diagnosed high-risk neuroblastoma.

                          Brand Name : Hu14.18K322A

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          August 01, 2023

                          Lead Product(s) : Dinutuximab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Renaissance Pharma

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          04

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Recordati will expand its pipeline by acquiring EUSA Pharma pipeline and enhances the breadth of indications which include Qarziba®, an anti-GD2 monoclonal antibody, Sylvant®, an anti-IL-6 monoclonal antibody, Fotivda®, an oral highly selective small ...

                          Brand Name : Qarziba

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          December 03, 2021

                          Lead Product(s) : Dinutuximab

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : Recordati

                          Deal Size : $847.0 million

                          Deal Type : Acquisition

                          blank

                          05

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : QARZIBA® is a monoclonal antibody that is specifically directed against the carbohydrate moiety of disialoganglioside 2 (GD2), which is overexpressed on neuroblastoma cells.

                          Brand Name : Qarziba

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          November 09, 2020

                          Lead Product(s) : Dinutuximab

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : BeiGene

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The DISTINCT trial did not meet its primary efficacy objective of extending the overall survival with Unituxin and irinotecan versus using irinotecan alone.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          February 03, 2020

                          Lead Product(s) : Dinutuximab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank